H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $47.00 price target on Travere Therapeutics (NASDAQ: TVTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments